In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Risk factors for chronic lymphocytic leukemia (CLL) include having a family history of CLL, being over the age of 50, exposure to certain chemicals, your biological sex, and your race. Chronic ...

One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

These quiz questions about chronic lymphocytic leukemia (CLL) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician ...

Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of ...